Transgene: Clinical Trials

24 trials sponsored by Transgene, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 7 terminated, 2 active not recruiting, 2 unknown. 16 Phase 1, 16 Phase 2, 2 Phase 3, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 116Completed 6, Terminated 5, Active not recruiting 2, Unknown 2, Recruiting 1
Phase 216Completed 6, Terminated 6, Active not recruiting 2, Unknown 2
Phase 32Completed 1, Terminated 1
Not applicable1Completed 1

Follow Transgene: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer
BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody) - Rectal Cancer Patients
Phase 1RecruitingHenry Smith202026-10-232026-11-04
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
TG6050 - Non-small Cell Lung Cancer
Phase 1TerminatedTransgene222023-04-052025-07-09
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
BT-001, Pembrolizumab [KEYTRUDA®] - Metastatic Cancer, Soft Tissue Sarcoma
Phase 1 / Phase 2TerminatedTransgene312021-02-252025-11-21
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
TG6002, Flucytosine (5-FC) - Colorectal Neoplasms
Phase 1 / Phase 2TerminatedTransgene152020-01-172023-06-23
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
TG4050 - Squamous Cell Carcinoma of Head and Neck
Phase 1 / Phase 2Active not recruitingTransgene802019-12-122026-01-16
A Trial Evaluating TG4050 in Ovarian Carcinoma.
TG4050 - Ovarian Carcinoma, Fallopian Tube Cancer
Phase 1CompletedTransgene642019-12-092025-11-14
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
TG6002, Flucytosine (5-FC, Ancotil) - Colorectal Neoplasm, Digestive System Neoplasm
Phase 1 / Phase 2TerminatedTransgene512018-10-162023-06-23
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
TG4010, Chemotherapy, Nivolumab - Non Small Cell Lung Cancer Metastatic
Phase 2CompletedTransgene442018-01-052022-01-11
Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients
Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®) - Glioblastoma, Brain Cancer
Phase 1 / Phase 2UnknownAssistance Publique - Hôpitaux de Paris782017-10-122017-11-06
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
TG4001, Avelumab - HPV-Related Carcinoma, HPV-Related Cervical Carcinoma
Phase 1 / Phase 2Active not recruitingTransgene1432017-09-012026-02-05
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Pexastimogene Devacirepvec (Pexa Vec), Nivolumab - Hepatocellular Carcinoma (HCC)
Phase 1 / Phase 2TerminatedTransgene142017-07-272021-11-19
Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.
Pexa-Vec, Ipilimumab - Metastatic Tumor, Advanced Tumor
Phase 1CompletedCentre Leon Berard222017-01-032022-07-25
TG4010 and Nivolumab in Patients With Lung Cancer
TG4010, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
Phase 2CompletedMegan Daly, MD132016-12-142025-11-10
Safety and Tolerability of TG1050: A Dose-finding Study
TG1050, Placebo - Chronic Hepatitis B
Phase 1CompletedTransgene482015-10-012018-11-27
A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
Cyclophosphamide and JX-594 dose escalation, Cyclophosphamide and JX-594, Cyclophosphamide - Solid Tumors, Soft-tissue Sarcoma
Phase 1 / Phase 2UnknownInstitut Bergonié1972015-09-182022-02-02
Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection
blood draw - Chronic Hepatitis B
Not applicableCompletedTransgene1662014-12-012016-02-02
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
TG4010, placebo - Non-Small-Cell Lung Carcinoma
Phase 2 / Phase 3TerminatedTransgene2222012-04-012017-01-05
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
JX-594, Irinotecan - Colorectal Carcinoma, CRC
Phase 1 / Phase 2CompletedJennerex Biotherapeutics522012-01-012026-08-05
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
pegylated interferon and ribavirin, TG4040 + SOC - Chronic Hepatitis C Infection
Phase 2CompletedTransgene1402010-05-012013-08-13
Trial of TG4023 Combined With Flucytosine in Liver Tumors
MVA-FCU1, flucytosine - Hepatocellular Carcinoma
Phase 1CompletedTransgene162009-09-012014-07-16

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (6)  ·  Colorectal Neoplasms (4)  ·  Carcinoma, Hepatocellular (2)  ·  Hepatitis B, Chronic (2)  ·  Neoplasm Metastasis (2)  ·  Rectal Neoplasms (2)  ·  Sarcoma (2)  ·  Vaccinia (2)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Merkel Cell (1)  ·  Colonic Neoplasms (1)  ·  Digestive System Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Glioblastoma (1)

Interventions

Flucytosine (4)  ·  Nivolumab (3)  ·  TG4010 (3)  ·  avelumab (2)  ·  Bevacizumab (1)  ·  Blood Specimen Collection (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Drug Therapy (1)  ·  Erlotinib Hydrochloride (1)  ·  Gemcitabine (1)  ·  Immunotherapy (1)  ·  Ipilimumab (1)  ·  Irinotecan (1)

Countries

France (20)  ·  United States (9)  ·  Germany (5)  ·  Belgium (4)  ·  Spain (4)  ·  Canada (3)  ·  Hungary (3)  ·  United Kingdom (3)  ·  Poland (2)  ·  Denmark (1)  ·  Israel (1)  ·  Italy (1)  ·  Switzerland (1)

Top investigators

Derek Jonker, MD (1)  ·  James Burke, MD (1)  ·  Karen Kelly (1)

Results publications

PMID 21699798, PMID 22019520, PMID 24063735, PMID 24586226, PMID 24657484, PMID 26727163, PMID 28177438, PMID 28923084, PMID 37506588, PMID 39060022, PMID 42744798

NIH funding

2014 (1), 2015 (1), 2025 (1), P30CA093373 (1)